JP2019163319A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019163319A5 JP2019163319A5 JP2019104081A JP2019104081A JP2019163319A5 JP 2019163319 A5 JP2019163319 A5 JP 2019163319A5 JP 2019104081 A JP2019104081 A JP 2019104081A JP 2019104081 A JP2019104081 A JP 2019104081A JP 2019163319 A5 JP2019163319 A5 JP 2019163319A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- acid sequence
- region
- sequence shown
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 40
- 239000007864 aqueous solution Substances 0.000 claims 20
- 239000003814 drug Substances 0.000 claims 8
- 229940079593 drug Drugs 0.000 claims 8
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 4
- 229930195725 Mannitol Natural products 0.000 claims 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 4
- 229930006000 Sucrose Natural products 0.000 claims 4
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 4
- 239000000594 mannitol Substances 0.000 claims 4
- 235000010355 mannitol Nutrition 0.000 claims 4
- 239000005720 sucrose Substances 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 2
- MFRNYXJJRJQHNW-DEMKXPNLSA-N (2s)-2-[[(2r,3r)-3-methoxy-3-[(2s)-1-[(3r,4s,5s)-3-methoxy-5-methyl-4-[methyl-[(2s)-3-methyl-2-[[(2s)-3-methyl-2-(methylamino)butanoyl]amino]butanoyl]amino]heptanoyl]pyrrolidin-2-yl]-2-methylpropanoyl]amino]-3-phenylpropanoic acid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MFRNYXJJRJQHNW-DEMKXPNLSA-N 0.000 claims 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 claims 1
- 230000004075 alteration Effects 0.000 claims 1
- 108010044540 auristatin Proteins 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 230000002209 hydrophobic effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021081392A JP7162695B2 (ja) | 2013-11-21 | 2021-05-13 | 抗体-薬物コンジュゲート凍結乾燥製剤 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361907001P | 2013-11-21 | 2013-11-21 | |
| US61/907,001 | 2013-11-21 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016533019A Division JP6590803B2 (ja) | 2013-11-21 | 2014-11-21 | 抗体−薬物コンジュゲート凍結乾燥製剤 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021081392A Division JP7162695B2 (ja) | 2013-11-21 | 2021-05-13 | 抗体-薬物コンジュゲート凍結乾燥製剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019163319A JP2019163319A (ja) | 2019-09-26 |
| JP2019163319A5 true JP2019163319A5 (enExample) | 2020-03-19 |
Family
ID=51947368
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016533019A Active JP6590803B2 (ja) | 2013-11-21 | 2014-11-21 | 抗体−薬物コンジュゲート凍結乾燥製剤 |
| JP2019104081A Pending JP2019163319A (ja) | 2013-11-21 | 2019-06-04 | 抗体−薬物コンジュゲート凍結乾燥製剤 |
| JP2021081392A Active JP7162695B2 (ja) | 2013-11-21 | 2021-05-13 | 抗体-薬物コンジュゲート凍結乾燥製剤 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016533019A Active JP6590803B2 (ja) | 2013-11-21 | 2014-11-21 | 抗体−薬物コンジュゲート凍結乾燥製剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021081392A Active JP7162695B2 (ja) | 2013-11-21 | 2021-05-13 | 抗体-薬物コンジュゲート凍結乾燥製剤 |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US10617764B2 (enExample) |
| EP (2) | EP4420729A3 (enExample) |
| JP (3) | JP6590803B2 (enExample) |
| KR (1) | KR102372245B1 (enExample) |
| CN (2) | CN113521016A (enExample) |
| DK (1) | DK3071237T3 (enExample) |
| ES (1) | ES2983564T3 (enExample) |
| FI (1) | FI3071237T3 (enExample) |
| HR (1) | HRP20241036T1 (enExample) |
| HU (1) | HUE068207T2 (enExample) |
| MX (1) | MX377841B (enExample) |
| PL (1) | PL3071237T3 (enExample) |
| PT (1) | PT3071237T (enExample) |
| SI (1) | SI3071237T1 (enExample) |
| WO (1) | WO2015075201A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SMT201700547T1 (it) * | 2010-06-15 | 2018-01-11 | Genmab As | Coniugati di farmaco anticorpo umano contro il fattore tissutale |
| DK3071237T3 (da) * | 2013-11-21 | 2024-09-09 | Genmab As | Lyofiliseret formulering af antistoflægemiddelkonjugat |
| WO2017009255A1 (en) * | 2015-07-10 | 2017-01-19 | Synthon Biopharmaceuticals B.V. | Compositions comprising antibody-duocarmycin drug conjugates |
| DK3347054T3 (da) | 2015-09-11 | 2021-07-19 | Genmab As | Dosisregimer til anti-TF-antistoflægemiddelkonjugater |
| DK3380525T3 (da) * | 2015-11-25 | 2024-01-29 | Immunogen Inc | Farmaceutiske formuleringer og fremgangsmåder til anvendelse deraf |
| US12115227B2 (en) | 2016-01-13 | 2024-10-15 | Genmab A/S | Formulation for antibody and drug conjugate thereof |
| SG11201810429UA (en) | 2016-06-27 | 2018-12-28 | Morphosys Ag | Anti-cd19 antibody formulations |
| CN106938051B (zh) * | 2016-08-22 | 2019-10-11 | 复旦大学 | 靶向于组织因子的抗体-药物偶联物 |
| JP7653013B2 (ja) | 2018-01-04 | 2025-03-28 | アイコニック セラピューティクス リミテッド ライアビリティ カンパニー | 抗組織因子抗体、抗体薬物コンジュゲート、及び関連する方法 |
| TWI841554B (zh) | 2018-03-21 | 2024-05-11 | 丹麥商珍美寶股份有限公司 | 以鉑為主之劑與抗組織因子抗體-藥物共軛物的組合治療癌症之方法 |
| CR20250325A (es) * | 2018-04-13 | 2025-08-29 | Genentech Inc | Formulaciones inmunoconjugadas anti-cd79b estables (divisional expediente 2020-0550) |
| UA130009C2 (uk) | 2018-05-07 | 2025-10-15 | Генмаб А/С | Спосіб лікування раку за допомогою комбінації антитіла до pd-1 і кон'югата антитіла до тканинного фактора і лікарського засобу |
| SG11202009986QA (en) | 2018-05-07 | 2020-11-27 | Genmab As | Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate |
| JP2021534165A (ja) * | 2018-08-16 | 2021-12-09 | ゲンマブ エー/エス | 抗組織因子抗体−薬物コンジュゲートおよびがんの治療におけるその使用 |
| TWI844571B (zh) | 2018-10-30 | 2024-06-11 | 丹麥商珍美寶股份有限公司 | 使用抗血管內皮生長因子(vegf)抗體與抗組織因子(tf)抗體-藥物共軛體之組合以治療癌症之方法 |
| MX2021009851A (es) | 2019-02-18 | 2021-09-10 | Lilly Co Eli | Formulacion de anticuerpos terapeuticos. |
| US20210077632A1 (en) * | 2019-08-15 | 2021-03-18 | Silverback Therapeutics, Inc. | Formulations of Benzazepine Conjugates and Uses Thereof |
| TW202131954A (zh) | 2019-11-07 | 2021-09-01 | 丹麥商珍美寶股份有限公司 | 利用鉑類劑與抗組織因子抗體-藥物共軛體之組合來治療癌症之方法 |
| AU2020380732A1 (en) | 2019-11-07 | 2022-06-02 | Genmab A/S | Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate |
| BR112022025105A2 (pt) | 2020-06-29 | 2023-01-17 | Genmab As | Método para o tratamento de câncer cervical em um indivíduo, conjugado anticorpo-fármaco, e, uso de um conjugado anticorpo-fármaco |
| JP2023547707A (ja) * | 2020-11-10 | 2023-11-13 | サノフイ | Ceacam5抗体-薬物コンジュゲート製剤 |
| WO2023036193A1 (zh) * | 2021-09-08 | 2023-03-16 | 同宜医药(苏州)有限公司 | 药物制剂及其制备方法和用途 |
| AU2022371507A1 (en) * | 2021-10-19 | 2024-05-02 | Coherent Biopharma (Suzhou) Limited | Conjugate drug preparation, preparation method therefor and use thereof |
| CN117045634B (zh) * | 2022-05-06 | 2025-10-10 | 北京康蒂尼药业股份有限公司 | 一种二肽衍生物组合物及其制备方法和用途 |
| US20250302982A1 (en) | 2022-05-06 | 2025-10-02 | Genmab A/S | Methods of treating cancer with anti-tissue factor antibody-drug conjugates |
| CN115656496A (zh) * | 2022-10-28 | 2023-01-31 | 迪瑞医疗科技股份有限公司 | 一种普适型冻干保护剂及其应用 |
| CN121039165A (zh) * | 2023-04-28 | 2025-11-28 | 江苏恒瑞医药股份有限公司 | 抗tf抗体和抗tf抗体-药物偶联物及其医药用途 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5223427A (en) * | 1987-03-31 | 1993-06-29 | The Scripps Research Institute | Hybridomas producing monoclonal antibodies reactive with human tissue-factor glycoprotein heavy chain |
| WO1989011297A1 (en) * | 1988-05-27 | 1989-11-30 | Centocor, Inc. | Freeze-dried formulation for antibody products |
| AU5093593A (en) * | 1992-08-28 | 1994-03-29 | Scripps Research Institute, The | Inhibition of tumor metastasis via neutralization of tissue factor function |
| US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
| US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| US5663149A (en) | 1994-12-13 | 1997-09-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides |
| MX9800684A (es) | 1995-07-27 | 1998-04-30 | Genentech Inc | Formulacion de proteinas liofilizadas isotonicas estables. |
| US5986065A (en) * | 1997-03-10 | 1999-11-16 | Sunol Molecular Corporation | Antibodies for inhibiting blood coagulation and methods of use thereof |
| DK0999853T3 (da) | 1997-06-13 | 2003-04-22 | Genentech Inc | Stabiliseret antostofformulering |
| US20040038878A1 (en) | 2000-08-04 | 2004-02-26 | Masahiko Tanikawa | Injectable protein formulations |
| GB0113179D0 (en) | 2001-05-31 | 2001-07-25 | Novartis Ag | Organic compounds |
| ATE454137T1 (de) | 2001-07-25 | 2010-01-15 | Facet Biotech Corp | Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab |
| US20030138417A1 (en) | 2001-11-08 | 2003-07-24 | Kaisheva Elizabet A. | Stable liquid pharmaceutical formulation of IgG antibodies |
| NZ537610A (en) | 2002-07-02 | 2006-07-28 | Smithkline Beecham Corp | Stable formulations of the C242 antibody |
| WO2004007557A2 (en) * | 2002-07-12 | 2004-01-22 | Novo Nordisk A/S | Tf antagonist |
| US20040033228A1 (en) | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
| AU2003293543A1 (en) | 2002-12-13 | 2004-07-09 | Abgenix, Inc. | System and method for stabilizing antibodies with histidine |
| ZA200506159B (en) | 2003-02-10 | 2006-10-25 | Elan Pharm Inc | Immunoglobulin formulation and method of preparation thereof |
| US7605235B2 (en) * | 2003-05-30 | 2009-10-20 | Centocor, Inc. | Anti-tissue factor antibodies and compositions |
| NZ583292A (en) | 2003-11-06 | 2012-03-30 | Seattle Genetics Inc | Monomethylvaline compounds capable of conjugation to ligands |
| WO2006014965A2 (en) | 2004-07-27 | 2006-02-09 | Human Genome Sciences, Inc. | Pharmaceutical formulation and process |
| US20070196364A1 (en) * | 2004-07-27 | 2007-08-23 | Human Genome Sciences, Inc. | Pharmaceutical Formulation and Process |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| JP2007034443A (ja) * | 2005-07-22 | 2007-02-08 | Konica Minolta Business Technologies Inc | 画像形成システム、画像形成装置及び画像形成処理方法 |
| ZA200800146B (en) * | 2005-08-03 | 2009-10-28 | Immunogen Inc | Immunoconjugate formulations |
| WO2007019232A2 (en) | 2005-08-03 | 2007-02-15 | Immunogen, Inc. | Immunoconjugate formulations |
| US10155816B2 (en) | 2005-11-28 | 2018-12-18 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
| CN101677987A (zh) * | 2007-06-22 | 2010-03-24 | 赛多斯有限责任公司 | 不含吐温80的多西他赛的增溶制剂 |
| KR20090001217A (ko) * | 2007-06-29 | 2009-01-08 | 삼성전자주식회사 | 미싱 노즐 검출방법 및 이를 이용하는 잉크젯 프린트 헤드 |
| JP4824710B2 (ja) * | 2008-02-08 | 2011-11-30 | 国立清華大学 | グラフト共重合体およびブロック共重合体の多機能混合ミセルならびにその製造方法 |
| UA109633C2 (uk) | 2008-12-09 | 2015-09-25 | Антитіло людини проти тканинного фактора | |
| JP5005023B2 (ja) * | 2009-12-25 | 2012-08-22 | インターナショナル・ビジネス・マシーンズ・コーポレーション | 読出し及び書込み命令の混在するコマンド列を受け取った場合の最適な書込みを実行するリニア記録方式の装置、その方法、及びプログラム。 |
| RS66008B1 (sr) | 2010-03-10 | 2024-10-31 | Genmab As | Monoklonska antitela protiv c-met |
| KR102218495B1 (ko) * | 2010-03-22 | 2021-02-19 | 제넨테크, 인크. | 단백질-함유 제제의 안정화에 유용한 조성물 및 방법 |
| SMT201700547T1 (it) | 2010-06-15 | 2018-01-11 | Genmab As | Coniugati di farmaco anticorpo umano contro il fattore tissutale |
| DK3071237T3 (da) * | 2013-11-21 | 2024-09-09 | Genmab As | Lyofiliseret formulering af antistoflægemiddelkonjugat |
| DK3347054T3 (da) | 2015-09-11 | 2021-07-19 | Genmab As | Dosisregimer til anti-TF-antistoflægemiddelkonjugater |
-
2014
- 2014-11-21 DK DK14802428.4T patent/DK3071237T3/da active
- 2014-11-21 FI FIEP14802428.4T patent/FI3071237T3/fi active
- 2014-11-21 ES ES14802428T patent/ES2983564T3/es active Active
- 2014-11-21 JP JP2016533019A patent/JP6590803B2/ja active Active
- 2014-11-21 EP EP24177039.5A patent/EP4420729A3/en not_active Withdrawn
- 2014-11-21 HU HUE14802428A patent/HUE068207T2/hu unknown
- 2014-11-21 MX MX2016006488A patent/MX377841B/es unknown
- 2014-11-21 WO PCT/EP2014/075326 patent/WO2015075201A1/en not_active Ceased
- 2014-11-21 CN CN202110607250.1A patent/CN113521016A/zh active Pending
- 2014-11-21 US US15/038,235 patent/US10617764B2/en active Active
- 2014-11-21 SI SI201432096T patent/SI3071237T1/sl unknown
- 2014-11-21 KR KR1020167016066A patent/KR102372245B1/ko active Active
- 2014-11-21 EP EP14802428.4A patent/EP3071237B1/en active Active
- 2014-11-21 HR HRP20241036TT patent/HRP20241036T1/hr unknown
- 2014-11-21 CN CN201480073804.2A patent/CN106163567B/zh active Active
- 2014-11-21 PT PT148024284T patent/PT3071237T/pt unknown
- 2014-11-21 PL PL14802428.4T patent/PL3071237T3/pl unknown
-
2019
- 2019-06-04 JP JP2019104081A patent/JP2019163319A/ja active Pending
-
2020
- 2020-01-14 US US16/742,158 patent/US20200246477A1/en not_active Abandoned
-
2021
- 2021-05-13 JP JP2021081392A patent/JP7162695B2/ja active Active
-
2022
- 2022-12-13 US US18/065,196 patent/US20240091373A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019163319A5 (enExample) | ||
| US12121527B2 (en) | Anthracycline-based antibody drug conjugates having high in vivo tolerability | |
| KR100812658B1 (ko) | 향상된 세포독성 및 수율의 항-이지에프알브이 3,에스씨에프브이에스, 이에 기초한 면역독소, 및 이의 이용방법 | |
| JP6333882B2 (ja) | 抗体−薬剤コンジュゲート | |
| JP7718816B2 (ja) | 抗メソセリン抗体およびその抗体薬物コンジュゲート | |
| JP6616776B2 (ja) | 抗体−薬物複合体及び免疫毒素 | |
| ES2788864T3 (es) | Conjugados de anticuerpo-fármaco e inmunotoxinas | |
| JP6585600B2 (ja) | C末端軽鎖ポリペプチド伸長を含有する抗体、ならびにその複合体及びその使用方法 | |
| JP2021516960A5 (enExample) | ||
| US11278628B2 (en) | Pharmaceutical formulations and methods of use thereof | |
| JP2020509031A5 (enExample) | ||
| KR20160079890A (ko) | 항체-약물 접합체 동결건조 제제 | |
| CN1816356A (zh) | 药物缀合物组合物 | |
| KR102399028B1 (ko) | 이중-특이적 항원-결합 폴리펩티드 | |
| RU2020112280A (ru) | Конъюгаты анти-egfr антитело-лекарственное средство (adc) и их применение | |
| WO2004064787A3 (en) | Parenteral formulations of peptides for the treatment of systemic lupus erythematosus | |
| IL273384B2 (en) | Methods of preventing methionine oxidation in immunoconjugates | |
| CN119317447A (zh) | 抗可变muc1*抗体及其用途 | |
| CN113795513A (zh) | 抗外周淋巴结地址素抗体及其用途 | |
| US20240091372A1 (en) | Anti-doppel antibody drug conjugates | |
| US20170326252A1 (en) | Nanoparticles for Delivery of Agents to Glioblastoma Tumors | |
| HK1092730A (en) | Drug conjugate composition |